Product Description
Poziotinib is an investigational, orally administered, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 with exon 20 insertion mutations. (Sourced from: https://www.sppirx.com/347-spectrum-products-development-poziotinib.html)
Mechanisms of Action: ERBB2 Inhibitor,TK Inhibitor,EGFR Inhibitor,ERBB4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Non-Small-Cell Lung Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Spectrum
Company Location: HENDERSON NV 89052
Company CEO: Thomas J. Riga
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PINNACLE | P3 |
Suspended |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2027-12-25 |
|
| NCI-2017-00831 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2025-12-31 |
|
| JapicCTI-205304 | P2 |
Active |
Non-Small-Cell Lung Cancer |
2025-03-31 |
|
| SPI-POZ-501 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2024-10-24 |